Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.
A world free of pain. This is our shared vision.
To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.
A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.
In view of our vision of a world free of pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.
At Grünenthal, conducting our business responsibly is a core part of our company’s strategy and culture. As a global leader in pain management, Grünenthal aspires to create a positive impact for society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards.
At Grünenthal, we share the responsibility to act with integrity and conduct all of our research and business activities in compliance with applicable laws and regulations.
Our company has a clear vision of a world free of pain and we maintain a laser-sharp focus on this vision in everything we do – especially in our research and development activities.
We follow a holistic and solution-agnostic approach to deliver highly effective pain treatments, building our programmes on a firm foundation of human pathophysiology and solid human target validation.
Grünenthal’s therapeutic area strategy is pursuing four key indications: peripheral neuropathic pain, chronic postoperative pain, chronic low back pain, and osteoarthritis.
As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available.
We believe that success comes from close collaborations founded on a shared vision to develop innovative medicines for patients that suffer from diseases with high unmet needs.
We strengthen and develop our core markets Europe, North America, Latin America and Asia through acquisitions, asset deals, in-licensing, commercialization and distribution deals.
Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.
Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .
Aachen / Santiago de Chile, December 27, 2013. The Grünenthal Group today announced the acceptance of the public tender offer with respect to the acquisition of all issued and outstanding shares of Laboratorios Andrómaco S.A. Inversiones Gruchi Limitada, a subsidiary of Grünenthal GmbH, Germany, has acquired 81.59% of all issued and outstanding shares of Laboratorios Andrómaco S.A. through a public tender offer. The offer period ended on December 24, 2013. Shareholders of Laboratorios Andrómaco S.A. who tendered their shares receive CLP 332.48 per share in cash.
Aachen, Germany / Redwood City (California), USA – December 16, 2013 – Grünenthal Group today announced that the company entered into a commercial partnership with AcelRx Pharmaceuticals, Inc. for ZALVISO, a patient-controlled analgesia device for self-administration of sufentanil nanotablets by patients following surgery. The agreement covers the countries of the European Union, EEA and Australia. AcelRx will supply Grünenthal with the product and retains all rights in remaining countries including the US and Asia.
Aachen / Santiago de Chile, November 25, 2013. Inversiones Gruchi S.A., a subsidiary of Grünenthal GmbH Germany yesterday published its public tender offer for the purchase of all outstanding shares in Laboratorios Andrómaco S.A. (Securities Registry No. 704). Grünenthal offers CLP 332.48 per share in cash. The offer price represents a premium of 66.99% on the closing price of Sept 6, the last trading day before the disclosure of the agreement between major Laboratorios Andrómaco S.A. shareholders and Grünenthal.
Aachen, October 28, 2013 – 96 million Europeans suffer from chronic pain.1,2 21% of these people have been affected for more than 20 years. Across Europe chronic pain accounts for nearly 500 million lost working days per year – costing the European economy around € 34 billion.1 However, the average period between initial symptoms of chronic pain disease and the beginning of adequate therapeutic intervention is four years, as shown by a recent study in Germany.3
Aachen, Germany, October 12, 2013. Today´s third International Day Against Pain is designed to give a voice to people suffering from pain, to provide information about the treatments that are available, to create a global alliance to broadcast the right to treatment and to raise funds for scientific research.
Florence, October 11th, 2013. – Worldwide millions of patients are tortured by a pain that is unexplainable for them. In a series of Meet-the-expert sessions hosted by Grünenthal at the 8th EFIC Pain in Europe congress in Florence, Italy, experts explained that in approximately 60% of cases, neuropathic pain is localized affecting a specific circumscribed area of the body.
Florence, October 10th 2013. As the field of pain has evolved significantly in Europe over the years, pain research is more relevant than ever: Every fifth adult citizen in Europe suffers from persistent or chronic pain, so pain has become a major health problem in Europe. In line with the thought that pain research is getting more and more important, the EFIC-Grünenthal Grant (E-G-G) gave young scientists support and a platform in the course of the 8th EFIC® Congress in Florence, Italy.
Aachen (Germany)/Santiago de Chile (Chile), September 9, 2013. Grünenthal, the international research-based pharmaceutical company headquartered in Aachen, Germany, has reached certain agreements with two major shareholders of Laboratorios Andrómaco S.A to enter into an in-depth due diligence process of the company. Following a successful completion of this due diligence, Grünenthal intends to launch a public tender offer for all outstanding shares of Laboratorios Andrómaco S.A. later this year followed by an effective closing of the transaction until end of 2013. Sergio Weinstein as one of the major shareholders intends to keep a significant stake in the company and remain as minority shareholder.
Aachen, September 9th 2013. The shareholders of the Grünenthal Group have assigned Dr. Wilhelm Moll, LL.M. (63) member of the supervisory board of the international pharmaceutical company headquartered in Aachen. In a meeting on September 6th, Dr. Moll was additionally elected chairman of the supervisory board. As of October 12th 2013 he will as well take over the responsibility of chairman of the advisory board of the Grünenthal Group. Furthermore, with effect from October 12th 2013 Edouard Croufer (66) has been elected member of the advisory board of Grünenthal Pharma GmbH & Co. KG and Grünenthal GmbH.
Aachen (Germany), 4. July, 2013 – At the end of June the Great Place to Work Institute® granted the Grünenthal Group the award of being one of the best employers in Europe. A few weeks before, the pharmaceutical company, specialists in pain research, with headquarters in Aachen, Germany, were pleased to receive the equivalent prize for the Latin American region.
Aachen (Germany) / Bogota (Colombia), November 6th 2013. The Grünenthal Group has signed an agreement with the Colombian pharmaceutical company BIOGEN® LABORATORIOS to take over one of its product portfolios including the corresponding trademarks. BIOGEN® LABORATORIOS has been operating in the market for more than thirty years.
Brussels/Aachen, 6 June, 2013. For the 8th time the European Federation of IASP® Chapters (EFIC®) in cooperation with the pharmaceutical company Grünenthal Group announced the EFIC-Grünenthal-Grant (E-G-G) – a grant aimed to support young scientists at an early stage of their experimental projects on clinical and human volunteer-based pain research.
Brussels / Belgium, 22 May, 2013.During the two SIP Focus Groups, which took place in Brussels on 14-15 May, the multi-stakeholder groups discussed and agreed upon two working documents for future policy actions: The SIP Recommendations paper on the “European Implementation of Quality Indicators in Chronic, Non-Malignant Pain Management” (Focus Group 1) and the SIP Proposal for Action, using “European Best Practices for the Reintegration of Chronic Pain Patients into the Workforce” (Focus Group 2).
Aachen (Germany), May 14, 2013 – Grünenthal Group achieved total revenues of €973 mn in 2012. Adjusted revenues (excluding revenues from divested businesses) rose by 13 percent. The increase was driven by growth of the global pain brands Palexia®/Tapentadol (up €36 mn) and Versatis®/Lidocaine patch (up €28 mn) as well as increased revenues from licences due to a successful product launch with Grünenthal´s INTAC® tamper resistant formulation technology. Revenues from the tapentadol license in the North American market increased as well. The revenue proportion of Grünenthal’s pain brands amounted to 73 percent of Group revenues (2011: 68 percent) and revenues from young pain products which have been launched a maximum of 5 years before 2012 reached about 30 percent, a significantly higher ratio than the industry average.
Aachen (Germany) / Chicago, IL (USA), April 19, 2013 – Grünenthal Group is pleased to announce their active participation in the 2013 BIO International Convention, the world’s largest event for the biotechnology industry. The family owned, research driven pharmaceutical company headquartered in Aachen, Germany, will be sharing with the Biotech community exciting developments in the NCE pipeline for pain and inflammation as well as the tamper-resistant formulation technology INTAC®.
Aachen, 17th April 2013 – Grünenthal is pleased with the U.S. Food and Drug Administration’s (FDA) recent decisions regarding abuse deterrent formulations (ADF) and prescription opioids. In its response to a citizen petition by Purdue, generic equivalents to the reformulated abuse deterrent formulation of OxyContin will be required to have similar abuse deterrent properties and undergo specific testing requirements to demonstrate these properties.
Aachen (Germany), 29 May, 2013. Grünenthal’s Supervisory Board has decided a reorganization of the Corporate Management structure of the international pharmaceutical company with headquarters in Germany. To enable the realization of our corporate strategy, especially accelerating organic as well as external growth in Latin America, all required sources will now be focused under the leadership of Prof. Eric-Paul Pâques.
Aachen, Germany, May 29, 2013 – The Grünenthal Group announced today that they have entered into a licensing agreement with Purdue Pharma L.P. regarding certain intellectual property rights for the development of an abuse-deterrent formulation technology for extended-release morphine sulfate.
Brussels/Belgium, 06 March, 2013. This year the European, multi-stakeholder platform “Societal Impact of Pain” (SIP) will organise their annual meeting in the form of SIP 2013 Focus Groups, which will be hosted in the EU Economic & Social Committee and the EU Parliament in Brussels, Belgium on 14-15 May. The aim of the SIP Platform is to raise awareness of the impact of chronic pain, to exchange information and share best-practices across the European Union and to develop and foster policy strategies and activities to improve pain care in Europe.
Aachen, March 6th 2013. The Grünenthal Group, a global leader in pain therapy with headquarters in Aachen, Germany concludes an exclusive license, distribution and supply agreement with Ethypharm, a French company that is specialized in the development of innovative formulation technologies. The agreement allows the company to commercialize Ethypharm's fentanyl sublingual tablets for the treatment of breakthrough cancer pain in selected European markets.
Aachen, 4th March 2013 – Today, the Grünenthal Group announced the appointment of Yugo Takahashi to assume the position of General Manager, Grunenthal Farmaceutica do Brasil, effective February 27th, 2013. Yugo Takahashi will be based in São Paulo and will report directly to Oscar Ferenczi, Executive Vice President Latin America of the Grünenthal Group.
Aachen, 18 February 2013 – Today, the Grünenthal Group announced the appointment of Oscar Ferenczi to Executive Vice President for the SBU Grünenthal Latin America with immediate effect. In his responsibility he will also take over the task of General Manager Grünenthal S.A. Panama, the regional head office of the company in Latin America, as well as General Manger Grünenthal Latin America, Miami.
Aachen, Germany, December 2nd 2013. The Grünenthal Group today announced that the supervisory board of the international pharmaceutical company prolonged the contract with the chairman of its Corporate Executive Board, Professor Dr. Eric-Paul Pâques, ahead of time and confirmed him in office as Chief Executive Officer for another three years. Professor Pâques had taken over the leadership of the pain specialist with its international headquarters in Aachen in May this year.
Aachen, 12 February 2013 – Today, the Grünenthal Group announced the appointment of Chief Executive Officer, Harald F. Stock, PhD. to the Board of Directors of OvaScienceSM. The life sciences company headquartered in Cambridge, Massachusetts (USA), focuses on the discovery, development and commercialization of new treatments for infertility.